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ABSTRACT. Biologics manufacturing technology has made great progress in the last decade. One of the
most promising new technologies is the single-use system, which has improved the efficiency of biologics
manufacturing processes. To ensure safety of biologics when employing such single-use systems in the
manufacturing process, various issues need to be considered including possible extractables/leachables
and particles arising from the components used in single-use systems. Japanese pharmaceutical manufac-
turers, together with single-use suppliers, members of the academia and regulatory authorities have
discussed the risks of using single-use systems and established control strategies for the quality assurance
of biologics. In this study, we describe approaches for quality risk management when employing single-use
systems in the manufacturing of biologics. We consider the potential impact of impurities related to single-
use components on drug safety and the potential impact of the single-use system on other critical quality
attributes as well as the stable supply of biologics. We also suggest a risk-mitigating strategy combining
multiple control methods which includes the selection of appropriate single-use components, their inspec-
tions upon receipt and before releasing for use and qualification of single-use systems. Communication
between suppliers of single-use systems and the users, as well as change controls in the facilities both of
suppliers and users, are also important in risk-mitigating strategies. Implementing these control strategies
can mitigate the risks attributed to the use of single-use systems. This study will be useful in promoting the
development of biologics as well as in ensuring their safety, quality and stable supply.
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INTRODUCTION
A single-use system is a system comprised of single-use
components, as the main apparatus/equipment. In recent
years, the use of single-use systems, such as single-use culture
bags in place of the conventional stainless steel culture tanks,
has been increasing in the manufacture of biologics (i.e. re-
combinant therapeutic proteins). Utilization of novel single-
use technologies has promising advantages that include in-
creased efficiency of manufacturing, including prevention of
cross contamination in the manufacture of high-potency com-
pounds, flexibility to manufacture multiple products and elim-
ination of the need for cleaning and steam sterilization
including those validations. However, this approach has also
raised new issues and concerns related to process control and
product quality assurance.
Based on accumulated scientific knowledge and quality
risk management concepts, this study identifies points that
need to be considered with respect to quality assurance for
biologics manufactured with single-use systems. The issues
described to ensure the quality of biologics manufactured
using single-use systems reflect generally accepted concepts,
but the individual risks and the development of a risk-
mitigating strategy should not be limited to these. In each
individual case, aspects raised in this study may be applied
selectively, but it is of paramount importance that the risks are
appropriately assessed according to technological advances
and the quality profile of the intended product and that ap-
propriate risk control is implemented correctly.
SCOPE
This study applies to single-use components, including
bags, filters, tubing, and connectors used in processes for
manufacturing biologic drug substance and drug products, as
well as systems comprised of single-use components. Drug
product containers (primary packaging), however, are outside
the scope of this study, since in these cases, the appropriate
requirements are stipulated by the pharmacopoeia (e.g. Japa-
nese Pharmacopoeia).
BASIC REQUIREMENTS
The quality assurance of biologics encompasses an eval-
uation of the raw materials as well as manufacturing process
controls for the drug substance and drug product. All proce-
dures must comply with ministerial regulation of good
manufacturing practice and the pharmacopoeia (e.g. Japanese
Pharmacopoeia) [1–15], in addition to other regional require-
ments [16–20], such as the Standard for Biological Ingredients
in Japan. ICH Q9 and other relevant guidelines [21–32] are
useful references for the general rules and procedures recom-
mended for quality risk management. Identification of the
risks that affect quality, efficacy, safety and stable supply of
biologics and the establishment of control strategies are basic
requirements for the development of a manufacturing process
of biologics using single-use systems. These risk management
processes should be shared between the relevant parties.
There are important elements in quality systems that are
intended to improve the quality and stable supply of biologics.
Establishing quality control strategies on the basis of
appropriate risk assessments is beneficial to ongoing improve-
ment throughout the biologics lifecycle, as well as communi-
cation between single-use component suppliers, end users and
regulatory authorities.
RISK ASSESSMENT
Risk factors associated with the use of single-use systems
may be related to product quality or to the stable supply of
biologics. Risks should be identified, and the magnitude of the
risk should be estimated using standard risk management
practices, which evaluate attributes such as impact and uncer-
tainty, or severity and likelihood. An identified risk should be
analysed and compared to risk criteria to decide whether it is
acceptable or should be mitigated. The tools that may be used
for risk assessment include qualitative techniques such as a
risk matrix and semi-quantitative techniques such as risk
scores. ICH Q9 is a useful reference for a detailed description
of risk assessment.
Impact on the Quality of Biologics
Residual Impurities
One of the quality-related issues resulting from the use
of single-use components is the risks of residual impurities
including leachables, insoluble particulate matter and insol-
uble visible matter (hereinafter termed single-use compo-
nent-related impurities). These impurities could be the
critical quality attributes (CQAs) of drug substance/drug
product by themselves. In order to avoid potential health
hazards, a list of all the impurities that might be introduced
into the manufacturing process should be prepared and
subjected to risk assessment to identify risks that should
be controlled. Information provided by suppliers about the
raw materials, manufacturing process, test results and prior
experience may be used in addition to the results of tests
conducted by end users.
Extractables and Leachables
Chemicals derived from single-use components that are
introduced into the process solution under conditions of ex-
aggerate temperature, pH or solvent are called extractables,
whereas chemicals that migrate under actual process condi-
tions are termed leachables [33–36]. Extractables/leachables
may include a variety of chemicals or their derivatives used in
the manufacture of single-use components such as catalysts,
polymeric initiators, excipients (e.g. antioxidants, lubricants,
anti-tack and anti-static agents), oligomers with a low degree
of polymerization, adhesives, anchoring agents, adhesive
resins and irradiation-induced degradation products and
oxides.The chemical profiles of leachables should be identi-
fied to the extent possible and feasible on the basis of test
results for extractables provided by the supplier, and as nec-
essary by conducting tests on the actual manufacturing process
solutions or on simulations, under conditions designed to
mimic worst case scenarios. If test results for extractables
provided by the supplier are to be used when evaluating
leachables, a determination should be made as to whether
the extractables preparation procedures and analytical
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methods are appropriate. Sterilization of single-use compo-
nents by radiation can also result in additional extractables/
leachables; hence, the sterilization conditions have an impor-
tant role when using test results for extractables provided by
the supplier and should be clearly specified. The necessity to
test for leachables in either the process solution or a simula-
tion arises when they are difficult to predict from the test
results for extractables, or when it is considered possible that
a new moiety, may be eluted during the manufacturing
process.Risk assessments for all possible leachables should
be conducted, and permitted ranges should be defined for
chemicals that are considered to require control. Toxicity
evaluations should be conducted when analysing and evaluat-
ing risk.
Insoluble Particulate Matter
In this study, insoluble particulate matter is defined as any
invisible insoluble impurity derived from a single-use compo-
nent and is distinguished from insoluble visiblematter. Insoluble
particulate matter may derive from an airborne solid in a single-
use component manufacturing facility or raw materials or com-
ponents used in the process of manufacturing the single-use
components. Theremay be various insoluble particulatematters
of different composition and particle size.As discussed for the
leachables, tests for insoluble particulate matter, generally using
water, should be conducted with reference to the information
provided by the supplier (e.g. raw material, manufacturing pro-
cesses, manufacturing environment, procedures to control insol-
uble particulate matter). Existence and characteristics of
insoluble particulate matter derived from single-use compo-
nents should be identified, to the extent possible and feasible.
The Japanese Pharmacopoeia ([4] <6.07> BInsoluble particulate
matter for injections^), as well as the European Pharmacopoeia
([13] <2.9.19> BParticulate contamination: Sub-visible
particles^) and the US Pharmacopoeia ([9] <788> Particulate
matter in injections), adopts the harmonized general chapter
and sets the control ranges for insoluble particulate matter of
over 10 and 25 μm in diameter (Fig. 1). Accordingly, such
insoluble particulate matter in a drug product should be con-
trolled. Risk assessments should be undertaken and control
ranges defined for insoluble particulate matter of a size outside
the scope of the pharmacopoeia or for new materials not previ-
ously detected in drug products, if necessary.
Insoluble Visible Matter (Visible Particle)
In this study, insoluble visible matter is defined as any
visible impurity adhering to or embedded in the inside (pro-
cess contact surface) or outside of a single-use component.
Insoluble visible matter may be derived from a worker, air-
borne solids or components present in a manufacturing facility
of single use suppliers. If peristaltic pumps are used, insoluble
visible matter may be released from the tubing.Each pharma-
copoeia lists the requirements for such insoluble visible mat-
ter, and drug products must meet these acceptance criteria;
(e.g. Japanese Pharmacopoeia (JP) <6.06> BForeign insoluble
matter test for injections^ [3], US Pharmacopoeia (USP)
<790> BVisible particulates in injections^ [10] and European
Pharmacopoeia (EP) <2.9.20> BParticulate contamination:
Visible particles^ [14]). Control ranges for insoluble visible
matter in manufacturing processes should be established while
bearing in mind that the visible detection limits of insoluble
visible matter depend on factors such as the environment in
which the visual inspection is conducted and on the transpar-
ency of the single-use component.
Endotoxins and Microbes
Endotoxins and microorganisms are other impurities that
could affect the drug substance/drug product and require con-
trol, particularly for injectables, where contamination with
endotoxins and microorganisms could negatively impact the
health of the patient.
Impact on CQAs
An additional quality-related event impacted by the use of
single-use components is deviation of the CQAs of biologics
from the appropriate limits, range and distribution. Possible
deviations include reduced concentration of the contents due
to adsorption to the single-use component, changes in aggregate
content, changes in the molecular variant content of intended
substances such as oxidants and changes in stability.
The magnitude of the risk (impact and uncertainty, or
severity and likelihood) arising from the use of single-use
components should be estimated for each CQA. Useful fac-
tors for estimating the level of risk include the chemical com-
position of the single-use component, the surface structure,
the profile of extractables/leachables, content of endotoxins
and microbes, material attributes such as the profile of insol-
uble particulate matter impurities, the extent of contact be-
tween the single-use component and the process (surface area,
time, temperature, agitation), the pH and conductivity of the
process solution, as well as the operational procedure. The
magnitude of the risks relevant to the usage or quality of the
single-use component should be compared to the risk criteria,
and their acceptability should be justified. In this instance, the
control range of CQAs is the risk acceptance criteria and the
extent and frequency of deviation from the CQA control
range may be considered in risk evaluation.
Impact on Stable Supply of Biologics
Another event affected by the use of single-use compo-
nents is the stable supply of biologics. Factors that could
impact the stable supply of biologics are the quality and prop-
er usage of single-use components as well as the certainty of
their supply chain.
Among the quality attributes of single-use components, the
impact of integrity and sterility is potentially large. Leachables
from single-use bags for cell culture can have a significant effect
on cell growth and metabolism, and deviations in process control
can be disruptive, thereby affecting the stable supply of biologics.
As for proper usage of single-use components, factors
that could impact the stable supply of biologics include trans-
portation, storage, unpacking, set-up, connection with connec-
tors or other components, as well as the operations in the
biologics manufacturing processes and the skill of the opera-
tors. In addition to a potential direct effect on manufacturing
operations, these factors could also cause leaks, affect the
integrity (seal performance) or sterility of single-use
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components, and indirectly impact stable supply as a result of
contamination. Leaks resulting in a contamination of the
manufacturing environment and possible exposure of the op-
erator to hazards could also disrupt the stable supply of
biologics.
Factors relevant to single-use component quality and
usage should be identified, and risk assessments should be
conducted to determine the need for relevant controls.
RISK CONTROL STRATEGIES
Risk control strategies should be determined on the basis
of risk assessment to avoid hazards to health, discard or supply
interruption of the biologics. For this purpose, it is useful to
conduct a risk assessment or more specifically, identification,
analysis and evaluate the risks in the manufacturing processes
that affect the impurities or other CQA (previous section).
Critical process steps and critical process parameters (CPP)
should be identified to prioritize the requirements for
controls.
Risk controls include various measures such as
avoiding, mitigating and removing the source of the risks.
One option for averting a health hazard is to avoid using
any single-use components whose impact on health or
whose leachables are uncertain, until further individual test-
ing is done. Risks leading to out-of-specification results or
delay of supply of biologics may be mitigated by judicial
selection of appropriate single-use components, by setting
their specifications, by carrying out appropriate design,
evaluation, and control measures for their use in the
manufacturing of biologics. If the combination of the quality
control strategies for the single-use components and the
manufacturing process of biologics are insufficient to avoid
risk, it may be useful to also include the specifications for
the drug substance/drug products. It is possible to confirm
the validity of established manufacturing processes for bio-
logics through process validation.
When selecting control methods, end users should take
the severity, probability and detectability of deviations in pro-
cess parameters into consideration. In general, it is preferable
to establish multiple control methods for each CQA. When
establishing control strategies, there should be cooperation
between the R&D, process development, manufacturing and
procurement departments of the biopharmaceutical industry,
in addition to the quality department.
Selection of Appropriate Single-Use Components
To ensure the quality and stable supply of biologics after
considering the abovementioned risks, it is important to choose
single-use components suitable for the intended use, for which the
certainty of supply and quality is assured. Since these issues
primarily depend on controls determined by the supplier, it is
important to obtain the suppliers’ relevant quality systems infor-
mation and to select the single-use components whose quality has
been appropriately evaluated and controlled.
The factors that should be taken into consideration in-
clude the structural design of the single-use component includ-
ing the connector joints, raw material controls, manufacturing
environment controls, manufacturing process controls, sterili-
zation process controls, test procedures and reliability of re-
sults for extractables, test procedures and acceptance criteria
for insoluble particulate matter and insoluble visible matter,
shipping inspection, packaging/transport controls and change
management/notification between the supplier and their sub-
suppliers. It is important to select single-use components
whose quality has been appropriately controlled, so that dif-
ferences between individual components or lots do not affect
the quality of biologics.
If raw materials such as stearate derived from bovine fat
have been used in single-use component manufacturing pro-
cesses, they should meet the animal-free requirement criteria
(e.g. standard for biological ingredients in Japan). It is also
critically important to control endotoxins, insoluble
Fig. 1. Pharmacopoeia specifications of insoluble particulate matter and insoluble visible matter for
injections
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particulate matter and insoluble visible matter in single-use
components used in the manufacture of drug product
(Table I). Decisions to adopt single-use components should
be made after taking into account the technical information,
including the recommended conditions for use submitted by
the supplier, since they may have lower physical strength
compared to the materials used in conventional technologies
such as stainless-steel components.
Selection of single-use components should take into ac-
count the continuity of the supplier’s business and the existence
of any appropriate alternative materials, if necessary. For single-
use components fitted with sensors, attention should be paid to
the performance of the sensor including the reliability of mea-
surement, and the possibility that sensor constituents may affect
the quality of biologics, as well as the possibility that sensor
failure may impact the manufacturing process operations.
Where the single-use component is critical for the quality and
stable supply of biologics, the supplier should be audited and the
quality control systems in place should be checked periodically. It
is also useful to prepare a quality contract incorporating such items
as product standards/specifications of single-use component,
manufacturing processes for single-use components that affect
quality standards, record controls, storage conditions applicable
to the enduser, expiration dates, auditing, change controls, and the
means of notifying the end user of changes (Table II).
Single-Use Component Specifications/User Requirement
Specifications
Specifications for single-use components should be
established in cooperation with the supplier, and for critical
single-use components, the suitability of each lot should be eval-
uated. It is also useful to prepare documents listing the specific
user requirement specifications for single-use components com-
posed ofmultiple parts. For example, specificationsmay be set for
insoluble particulate matter, endotoxins and sterility.
Receipt of Single-Use Components and Their Inspection Be-
fore Release for Use
In contrast to fixed equipment processes where the actual
equipment is qualified and validated, in single-use systems, it
is not possible to use the single-use component identical to the
component that have been qualified in actual manufacturing
process because each component is used only once. Therefore,
it is necessary to check the component upon receipt and
before releasing for use, so that differences between individ-
ual single-use components or lots do not impact the quality or
manufacturability of biologics. Acceptance criteria similar to
those applied to raw materials should be defined for the
single-use components and applied before release for use. In
setting the list of such inspection, the intended usage of single-
use components in the biologics manufacturing process and its
impact on the quality of biologics should be taken into con-
sideration. Decisions concerning the inspection method and
acceptance criteria should preferably be made jointly by the
supplier and the end user to ensure maximum conformation to
the requirements of the end user. Items that should be
checked upon receipt include details of the shipping certifi-
cate, product labels, external appearance (visually check for
breakage or adherence of foreign matter) and details of any
irradiation certificate relevant for sterilization. To the extent
possible, it should be confirmed that the materials conform to
user requirement specifications and material specifications.
Inspection Before Release for Use
It is useful to determine storage conditions and to set
inspection before use for single-use component, because
breakage or contamination with insoluble visible matter
and component interconnections may sometimes be diffi-
cult to detect at the time of receipt or may occur later
during unpacking or storage. Items that should be checked
before use, include the manufacture date (warranty peri-
od), storage conditions between receipt and use, conformi-
ty to set up and configuration specifications, breakage (e.g.
visual inspection) and inspection for the presence of insol-
uble visible matter.
Qualification of the Single-Use System
Single-use system components should be evaluated as
discussed in BSingle-Use Component Specifications/User Re-
quirement Specifications^ section, and qualification should be
Table I. Examples of Points to Consider When Introducing Single-Use Components
Examples of lists to be assessed Examples of issues to be assessed
Structure design Shape, layered structure for preventing leachables,
compatibility with other components, structure
for preventing misuse, strength
Raw materials control Monomers, polymerization initiators, metal catalysts,
additives (antioxidants, lubricants, anti-adhesives, antistatics),
adhesives, printing inks, solvents, and biological ingredients
Manufacturing environment control Air cleanliness, airborne microorganisms
Manufacturing process control Inspections upon receipt of materials and components,
shape-forming, film-forming, bag-making, assembly, integrity test
Sterilization process control Radiation dosage (gamma- and beta-rays), level of ethylene oxide gas
Quality control Reliability of test procedure and analytical methods for extractables,
test procedure and acceptance criteria for insoluble particulate matter
Release test Appearance, integrity test, consistency with the drawings,
endotoxin test, inspection of foreign matters, sterility assurance
Packaging and delivery control Primary packaging, wrapping, transport
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carried out to confirm their suitability for the intended use. In
addition, single-use systems in which single-use components
are connected to fixed equipment/apparatus should undergo
design qualification (DQ), installation qualification (IQ),
operational qualification (OQ) and performance qualification
(PQ). Single-use systems should also be checked for consis-
tency with the intended design and requirement specifications,
and their correct function within the expected operating range
should be confirmed.
It should be noted that unlike fixed equipment or
apparatus installed in manufacturing facilities, in single-
use systems, single-use components identical to the compo-
nent that have been used in qualification cannot be used in
actual manufacturing. Attention should be paid to ensure
differences between individual single-use components or
lots do not impact the quality and manufacturability of
biologics.
Design, Evaluation and Control of the Manufacturing Process
for Biologics
Appropriate design, assessment and control of
manufacturing processes of drug substance and drug prod-
uct can reduce the possibility of deviation of CQAs and
minimize contamination by impurities from the single-use
components. One approach is to include a strategy for
elimination of impurities in the downstream purification
processes, although it is better to use single-use components
without this concern.
For an identified leachable impacting the biologics
quality and requiring control, it is useful to investigate
the parameters and processes involved in both the gener-
ation and elimination of the leachable, as well as the
probability and detectability of deviations of these pro-
cesses and parameters. Factors that can affect the gener-
ation of leachables include the composition of the process
solution, the extent of the contact with single-use compo-
nents (surface area, time, temperature and agitation) and
sterilization method such as gamma irradiation, while fac-
tors that can affect the elimination of leachables include
purification processes such as chromatography and UF/DF
process along with their process parameters. Thus, it is
possible to control leachables by incorporating steps for
their elimination in the design of the manufacturing pro-
cess of biologics and setting the control range of process
parameters and in-process testing. In some cases, it is
necessary to flush single-use components before use to
reduce the levels of not only residual insoluble particulate
matter but also soluble leachables.
When single-use components were used in sterile pro-
cess, it is also important to establish measures to ensure
continued sterility during usage, seal integrity after con-
nection to related process equipment, correct installation
and the integrity of the filtration sterilization processes. In
order to assure the integrity of the single-use components
such as sterilization filters, testing/controls after use may
be implemented, as necessary.
The mechanism by which the characteristics of single-use
components affect the quality of biologics is not completely
understood. Thus, single-use component-related impurities
such as leachables and insoluble particulate matter may affect
the quality of biologics but be undetected by current analyses.
Therefore, in addition to the single-use component quality
controls discussed here, consistency of the manufacturing pro-
cess of biologics is also important.
Table II. Examples of Information Normally Disclosed to Users by
Suppliers
Organization, equipment, quality control system of the single-use
component supplier
• General quality system
• Manufacturing facilities and environment (including
manufacturing area, layout of facilities such as warehouses, grade,
environmental management)
• Manufacturing supply capacity, delivery time, and supply system
• Procedure to develop or change specifications
• System to qualify the outsourcing contractors such as irradiation
sterilization vendors
• Staff education
• Business continuity plan
Methods for manufacturing and quality control
• Quality assurance by manufacturing process control (parts
identification, foreign material control, connection, integrity
test, sterilization, storage method, etc.)
• Prevention measures of operational error
• Control methods for foreign material
• List of foreign materials possessed by the supplier
• Control methods of foreign insoluble matter attached to or
embedded in single-use components
• Control methods of insoluble particulate matter
• Control methods for endotoxins
• Sterilization procedures and validation
• Qualification of each part of the single-use component
• Compatibility assessment of each part of the single-use
component
• Procedure and recording of line clearance (prevention of
contamination and wrong assembling, etc.)
• Process control, recording, operator education and qualification of
assembly
• Release tests (list of tests, methods, acceptance criteria, etc.)
• Validation methods for shipping
Test results of single-use component
• Extractables test (test methods including preparation condition of
extractables, analytical equipment used, results of analytical
method validation, etc.)
• Insoluble particulate matter test
• Mechanical strength test
• Gamma-ray irradiation resistance test
• Shelf time test
• Biological safety test
• Oxygen permeability test
• CO2 permeability test
• Vapour permeability test
• Solution drainage test
• Test methods for aseptic connection
• Other test required for an assessment of the performance of
single-use components
Others
• Warranty and expiration dates of the materials
• Storage methods of materials (temperature, humidity, necessity of
shielding, etc.)
• Contract testing of leachables
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Specifications of Biologics
In addition to selecting appropriate single-use compo-
nents and biologics manufacturing process controls, it is also
useful to establish specifications for the drug substance/drug
product with respect to residual single-use components-relat-
ed impurities or other CQAs, if necessary. Defining the spec-
ifications prevents the release of lots with out-of-specification
with regard to residual impurities or other CQAs.
Appropriate Training When Using Single-Use Component
Because single-use equipment is often operated manual-
ly, human error in unpacking, connecting, installation, and
operation of biologics manufacturing processes may affect
the stable supply and/or quality of the biologics. To avoid
human error, training systems should be implemented and
standard operational procedures should be provided to the
operators. It is also useful for end users and suppliers to jointly
undertake periodic operator training, with the additional aim
of upgrading technology, including knowledge and automated
systems, as appropriate.
Communication Between Single-Use Suppliers and End Users
It is preferable for the suppliers to disclose as much infor-
mation as possible regarding the source of chemicals and the
quality controls of the single-use components. If possible, it is
also preferable that the end user should disclose the purpose of
the single-use components in the biologics manufacturing pro-
cess to the supplier in order to avoid problems arising from
invalidated use. Communication between suppliers and end
users can be useful to confirm the appropriateness of selection
and usage of the single-use components employed in
manufacturing processes of biologics (Tables II and III).
Deviation Control
There are known incidents involving single-use compo-
nents, such as content leakage, although the frequency may be
low. Since manual operation is more common with single-use
systems than with conventional fixed equipment, technical
proficiency, such as in the assembling of components, is nec-
essary to avoid even infrequent incidents such as content
leakage. The appropriate responses in cases of deviations,
such as leakage or misconnection, should be set out before-
hand in accordance with the companies’ established and
GMP-compliant deviation handling standard operation proce-
dure (SOP). In the event of a deviation, measures should be
taken in accordance with the procedure, and corrective action
and preventive action (CAPA) should also be taken, as ap-
propriate and the choice of component should be reevaluated.
LIFE CYCLE AND CHANGE MANAGEMENT
In the life cycle management of biologics manufactured
using single-use systems, it is important to continually assess
whether the system employed is being operated as intended
and whether improvements or changes are required. In addi-
tion, change controls are an important factor in life cycle
management even if single-use components are used, because
many changes occur in manufacturing processes of biologics
due to scale changes in manufacture or implementation of new
technologies.
Possible changes at end users of single-use components
include a change of suppliers of the single-use components, a
change in a single-use component from the same supplier as
well as a change in the use of a single-use component. A risk
assessment of the impact on the quality of the biologics should
be undertaken for each change, in light of information pro-
vided by the supplier and the comparability assessed with
reference to the ICH Q5E guidelines, as necessary.
Possible changes in the single-use component supplier
include changes in the raw materials, parts used, place of
manufacture, manufacturing processes, sterilization processes,
quality testing, acceptance criteria of release test, packaging
and delivery. It is necessary for end users and suppliers to
establish in advance what changes might affect the quality of
single-use components, with consideration given to an ade-
quate period to investigate the effects of the change. Lot
control is required for single-use components as for raw ma-
terials and forms part of the control measures imposed on
biopharmaceutical industries.
In order to avoid any unexpected deleterious impact on
quality attribute due to the changes, suppliers and end users
should interact throughout the life cycle of the biologics
concerning the quality and purpose for use of the single-use
components. An agreement should be clearly established in-
dicating that information relevant to any implemented chang-
es will be provided. Collaboration between suppliers and end
users is also recommended in order to ensure a continual
improvement of biopharmaceutical quality throughout the
biologics life cycle. For such purpose, end users should per-
form supplier audits periodically to ensure that the suppliers
have an appropriate quality system.
CONCLUSION
Our intention is that this study will be useful in promoting
the development of biologics as well as in ensuring their safety,
quality and stable supply.
Table III. Examples of Information Normally Disclosed to Suppliers
by Users











• Use of peristaltic pump
• Maximum pressure
• Use of autoclave sterilization
• Flushing prior to use
• Stirring
• Filter integrity test (sterilization filter)
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From the international perspective, comments or sug-
gestions on this paper are appreciated. Please send com-
ments by email to BSU_jimukyoku@nihs.go.jpB, if any.
Valuable comments will be considered for the future reg-
ulatory environment regarding single-use system related
issues in Japan.
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A physical, chemical, biological, or
microbiological property or
characteristic that should be within an
appropriate limit, range, or distribution
to ensure the desired product quality.
Extractables: Chemical entities that are extracted
from single-use components into sol-
vents or fluid contents under exagger-
ate conditions. In this study, specifically,
extreme conditions are defined as con-
ditions that are favourable for transfer
of chemicals into solvents due to the
composition of the solvents, pH, tem-
perature, duration of contact, etc.,
compared to the general conditions for
the manufacturing process of biologics.
Insoluble visible
matter:
Impurities that are visually observed
and insoluble, and attached to or
embedded in single-use components.
Insoluble particulate
matter:
Insoluble particulate impurities that are
derived from single-use components.
Leachables: Chemical entities that are extracted
from single-use components into the
manufacturing process solution under
the general conditions of the process.
Process solution: A solution that contacts with single-use
components during the manufacturing
process of biologics.
Single use: Single use means that the component is




A component that is intended to be
used once (single use). Specifically,
single-use components include plastic
bags, filters, tubing, connectors,
solution-storage bottles, and sensors.
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